A Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Juvenile Idiopathic Arthritis (JIA)

Trial Profile

A Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Juvenile Idiopathic Arthritis (JIA)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BiKeR
  • Most Recent Events

    • 17 Jun 2017 Results (n=589) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 26 Dec 2015 New trial record
    • 11 Nov 2015 Interim results (n = 568) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top